Drug Utilization Evaluation of Rivaroxaban in Clinic of Shahid Madani Hospital in 1398

Abstract

Rivaroxaban is an oral anticoagulant drug that inhibits factor Xa directly. Rivaroxaban inhibits fibrin clot formation directly, selectively, and reversibly by inhibiting factor X in both internal and external ways. It is used in prevention and treament of thrombosis in cardiovascular disease and also in hip or knee joint replacement. Aim: To evaluate the adherence to AHA/ACC guidelines in patients who received rivaroxaban in Shahid Madani clinic of Tabriz University of Medical Sciences. Methods: This study was descriptive prospective drug utilization evaluation. It was performed in 8 months in the heart clinic of Shahid Madani hospital on patients taking rivaroxaban. Patients were randomly selected in two to three days a week. In this study, after obtaining patient satisfaction, patients' data were recorded in pre-designed questionnaire which include demographic data, past medical history and drug history.Then, the indications of rivaroxaban use compared with AHA/ACC guidelines and the results were presented in a descriptive manner. Results: During 8 months, a total of 80 patients with a mean age of 65.7 ± 13.9 were joined this study. The male to female ratio was almost equal and 22.5% of patients were smokers. Most patients had a family history of heart disease. In 76.25% of cases, the drug was prescribed correctly and was consistent with valid guidelines, and in the remaining cases, the drug dose was not rational for the disease. Conclusion: During the evaluations, the administration of rivaroxaban had a relatively high correlation with the AHA / ACC guidelines recommendations, but in some cases required further improvement. Clinical pharmacists with his or her knowledge and experience can choose the best appropriate instructions and help the doctors to prescribe the correct medication with better dosage